
Xiaolin Wu
Articles
-
Jun 17, 2024 |
mdpi.com | Yinsong Liu |Xiumei Zhang |Xiaolin Wu |Zhaowei Hou
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jun 3, 2024 |
nature.com | Wei-Xiang Sin |N. Jagannathan |Xiaolin Wu |Joshua Raymond |Yie Hou Lee |Qingfeng Chen | +3 more
AbstractThe manufacturing of autologous chimaeric antigen receptor (CAR) T cells largely relies either on fed-batch and manual processes that often lack environmental monitoring and control or on bioreactors that cannot be easily scaled out to meet patient demands.
-
May 9, 2024 |
mdpi.com | Min Wang |Haiwen Wei |Xiaolin Wu |Yinsong Liu
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Apr 30, 2024 |
mdpi.com | Hui Liu |Yangwei Mu |Xiaolin Wu |Yuxin Xuan
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Mar 28, 2024 |
nature.com | Eric V. Slud |Julián Candia |Xiaolin Wu |Jittiporn Chaisaingmongkol |Mathuros Ruchirawat |Zeynep Kacar | +1 more
AbstractHepatocellular carcinoma (HCC) is a molecularly heterogeneous solid malignancy, and its fitness may be shaped by how its tumor cells evolve. However, ability to monitor tumor cell evolution is hampered by the presence of numerous passenger mutations that do not provide any biological consequences.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →